The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Effect of Blockade of TNF-α and Interleukin-1 Action on Bone Resorption in Early Postmenopausal Women
Abstract
After acute estrogen withdrawal in postmenopausal women, administration of anakinra or etanercept, specific blockers of IL-1 and TNF-α, respectively, reduced the rise in bone resorption markers to about one half of that in controls. This is consistent with an important role for these immune cytokines in mediating the effect of estrogen deficiency on bone. Introduction: Studies in rodents have implicated increased production of interleukin (IL)-1β and TNF-α as mediators of bone loss after ovariectomy, but their roles are unclear in humans whose immune system differs markedly from that of rodents. Materials and Methods: We administered transdermal estradiol, 0.1 mg/d, for 60 days to 42 early postmenopausal women. Estrogen treatment was discontinued, and subjects were randomly assigned to intervention groups receiving 3 wk of injections with 0.9% saline, anakinra 100 mg/d, or etanercept 25 mg/twice weekly. Bone turnover was assessed by measuring serum carboxyl-terminal telopeptide of type 1 collagen (CTX) and amino-terminal telopeptide of type 1 collagen (NTX), markers for bone resorption, and serum amino-terminal propeptide of type 1 collagen (P1NP), a marker for bone formation. Results were expressed as percent change in markers from baseline (last 2 days of estrogen treatment and days 20 and 21 of intervention). Results: The percent changes from baseline during intervention for serum CTX, urine NTX, and serum PINP, respectively, were 43.3 ± 8.0%, 12.0 ± 7.1%, and −41.0 ± 2.5% for the control group; 25.9 ± 6.3%, 9.5 ± 4.0%, and −37.8 ± 3.0% for the anakinra group; and 21.7 ± 5.0%, 0.32 ± 3.82%, and −34.5 ± 3.9% for the etanercept group. Compared with the control group, the blunting of the increase in serum CTX fell just below the level of significance (p = 0.10) after anakinra treatment, whereas the blunting of the increase in serum CTX (p = 0.034) and in urine NTX (p = 0.048) were significant after etanercept treatment. Other changes were not significant. Conclusions: The data are consistent with a role for TNF-α, and possibly for IL-1β, in mediating increased bone resorption during estrogen deficiency in women. Although either cytokine blocker reduced serum CTX by about one half, the effect of combined blockade could not be tested because of concerns about toxicity. The data do not exclude direct or indirect contributory roles for RANKL or for other cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citationDenosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990 · cited 1×
“Subjects with any of the following criteria were excluded: (1) history of tuberculosis or a positive tuberculin skin test or the presence of other chronic inflammatory infectious disease, autoimmune disease, malignancy, neurological disease, thrombophlebitis, deep venous thrombosis, or previous osteoporotic fracture;…”
BackgroundRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“In addition, estrogen may decrease the RANKL/osteoprotegerin (OPG) ratio in the bone microenvironment.((24,25))”
BackgroundSelf-citationHofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Self-citationFalahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Self-citationPacifici, R., Brown, C., Puscheck, E., Friedrich, E., Slatopolsky, E., Maggio, D., McCracken, R., & Avioli, L. V. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5134 · Cited by 555
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021036 · Cited by 283 · cited 2×
“The early decrease in bone formation markers has been previously shown in older men receiving a GnRH agonist to induce pharmacologic hypogonadism,((15,23)) and in the study by Leder et al,((23)) bone formation began to increase after 12 wk as a result of the poorly understood coupling mechanism.”
BackgroundKimble, R. B., Matayoshi, A. B., Vannice, J. L., Kung, V. T., Williams, C., & Pacifici, R. (1995) · Endocrinology · doi:10.1210/endo.136.7.7789332 · Cited by 273
Cited by
Khosla, S., Oursler, M. J., & Monroe, D. G. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.008 · Cited by 943
Self-citationSex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics
Li, J.-Y., Chassaing, B., Tyagi, A. M., Vaccaro, C., Luo, T., Adams, J., Darby, T. M., Weitzmann, M. N., Mulle, J. G., Gewirtz, A. T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86062 · Cited by 643
“The contributing influences of IL-1 and TNF in humans was underscored by reports showing that menopause increases the levels of both of these immune factors (32–35), while treatment with TNF and IL-1 inhibitors prevents the increase in bone resorption that results from estrogen deficiency (36).”
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Current Advances in Immunomodulatory Biomaterials for Bone Regeneration
Lee, J., Byun, H., Madhurakkat Perikamana, S. K., Lee, S., & Shin, H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801106 · Cited by 452
Probiotics Protect Mice from Ovariectomy-Induced Cortical Bone Loss
Ohlsson, C., Engdahl, C., Fåk, F., Andersson, A., Windahl, S. H., Farman, H. H., Movérare-Skrtic, S., Islander, U., & Sjögren, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092368 · Cited by 339
Regulation of Bone Metabolism by Sex Steroids
Khosla, S., & Monroe, D. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031211 · Cited by 323
Self-citationNovack, D. V. (2011) · Cell Research · doi:10.1038/cr.2010.159 · Cited by 315
Glucocorticoid-induced osteoporosis
Briot, K., & Roux, C. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000014 · Cited by 300
The Pathophysiology and Treatment of Osteoporosis
Drake, M. T., Clarke, B. L., & Lewiecki, E. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.006 · Cited by 290
McCabe, L. R., Irwin, R., Schaefer, L., & Britton, R. A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24340 · Cited by 273
Li, J., Chen, X., Lu, L., & Yu, X. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.003 · Cited by 273
Yang, N., Wang, G., Hu, C., Shi, Y., Liao, L., Shi, S., Cai, Y., Cheng, S., Wang, X., Liu, Y., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1798 · Cited by 255
Clarke, B. L., & Khosla, S. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.02.014 · Cited by 221
Self-citationModulation of bone remodeling by the gut microbiota: A new therapy for osteoporosis
Lyu, Z., Hu, Y., Guo, Y., & Liu, D. (2023) · Bone Research · doi:10.1038/s41413-023-00264-x · Cited by 207
Grassi, F., Tell, G., Robbie-Ryan, M., Gao, Y., Terauchi, M., Yang, X., Romanello, M., Jones, D. P., Weitzmann, M. N., & Pacifici, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703610104 · Cited by 150
Estrogen deficiency, T cells and bone loss
Pacifici, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.06.008 · Cited by 146
Ali, D., Tencerova, M., Figeac, F., Kassem, M., & Jafari, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.981487 · Cited by 122
“A number of underlying pathogenic mechanisms of osteoporosis have been proposed, such as estrogen deficiency-associated Bone Marrow (BM) inflammation (8) or decreased levels of anabolic hormones (9, 10).”
BackgroundLi, L., Rao, S., Cheng, Y., Zhuo, X., Deng, C., Xu, N., Zhang, H., & Yang, L. (2019) · MicrobiologyOpen · doi:10.1002/mbo3.810 · Cited by 109
From osteoimmunology to osteomicrobiology: How the microbiota and the immune system regulate bone
Hsu, E., & Pacifici, R. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0321-0 · Cited by 106
Bone Remodeling and the Microbiome
Pacifici, R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031203 · Cited by 101
“…increases the levels of both of these immune factors (Pacifici et al. 1989, 1991; Cohen-Solal et al. 1993; Bernard-Poenaru et al. 2001), whereas treatment with TNF and IL-1 inhibitors prevents the increase in bone resorption that results from estrogen deficiency (Charatcharoenwitthaya et al. 2007).”
BackgroundRestoration of regenerative osteoblastogenesis in aged mice: Modulation of TNF
Wahl, E. C., Aronson, J., Liu, L., Fowlkes, J. L., Thrailkill, K. M., Bunn, R. C., Skinner, R. A., Miller, M. J., Cockrell, G. E., Clark, L. M., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090708 · Cited by 56
Metadata
- Authors
- Charatcharoenwitthaya, N., Khosla, S., Atkinson, E. J., McCready, L. K., & Riggs, B. L.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 22
- Issue
- 5
- Pages
- 724-729
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2002306991
- Cited by
- 235
- References
- 10
- FWCI
- 13.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.